Are inhaled long-acting beta-agonists (LABA) really harmful in adult asthmatics?
AbstractMr. SS, a 32 year old Chinese male, is a known case ofmoderately severe persistent asthma since the past 17 years.He is a palm oil plantation worker for the past 6 years. He is anon- smoker, non-hypertensive and has no history of diabetesmellitus. There is a family history of bronchial asthma in bothhis mother and maternal grandfather. On examination, thepatient appears tachypnoeic, with a respiratory rate of 30breaths per minute. His pulse rate is 110 beats per minute.Peak expiratory flow done at the time of clinical examinationis 200 L/min. He is currently on a combination of fluticasonepropionate (250 mcg) and salmeterol (50 mcg) administeredby an inhaler device twice a day. He has heard that the use ofinhaled long-acting beta agonists (LABA) is consideredcontroversial and potentially damaging and is thereforeconcerned about further usage of this therapy. (copied from article)
O’Byrne P. Pharmacologic interventions to reduce the risk of asthma exacerbations. Proc Am Thorac Soc. 2004; 1(2):105-8.
Pauwells RA, Lofdahl C, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405-11.
Walters EH, Walters JAE, Gibson MDP. Long-acting beta2-agonists for stable chronic asthma. Cochrane Database Syst Rev. 2003, Issue 3. Art.No. CD001385. DOI: 10.1002/14651858.CD001385.
Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320(7246):1368-73.
Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroid in symptomatic asthma. Thorax. 2005;60(9):730-4.
Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol. 1996;49(2):247-50.
Williams C, Crossland L, Finnerty J, et al. Case control study of salmeterol and near fatal attacks of asthma. Thorax. 1998;53(1):7-13.
Jenkins C, Woolcock AJ, Saarelainin P, et al. Salmeterol/ fluticasone propionate combination therapy 50/250 micrograms twice daily is more effective than budesonide 800 micrograms twice daily in treating moderate to severe asthma. Respir Med. 2000;94(7):715-23.
Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306(6884):1034-7.
Nelson H, Weiss S, Bleecker E, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26.
Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta analysis: effect of long-acting â-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144(12):904-12.
Johnson M. Molecular mechanisms of beta-2 adrenergic receptor function, response and regulation. J Allergy Clin Immunol. 2006;117(1):18-24.
Wechsler M, Israel E. How pharmacogenetics will play a role in the management of asthma. Am J Respir Crit Care Med. 2005;172(1):12-8.
Lazarus SC, Boushey HA, Fahy J, et al. Long-acting betaagonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. A randomized controlled trial. JAMA. 2001;285(20):2583-93.
van den Toorn LM, Overbeek SE, de Jongste JC, et al. Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med. 2001;164(11): 2107-13.
de Kluijver J, Evertse CE, Schrumpf JA, et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: protection by inhaled steroids. Am J Respir Crit Care Med. 2002;166(3):294-300.
Mc Fadden ER Jr, Warren EL. Observations on asthma mortality. Ann Intern Med. 1997;127(2):142-7.